Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy

<h3>Background</h3><p dir="ltr">Cardiac troponin I (<i>TNNI3</i>) gene mutations account for 3% of hypertrophic cardiomyopathy and carriers have a heterogeneous phenotype, with increased risk of sudden cardiac death (SCD). Only one mutation (p.Arg21Cys) has be...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Akl C. Fahed (11514346) (author)
مؤلفون آخرون: Georges Nemer (295984) (author), Fadi F. Bitar (19239475) (author), Samir Arnaout (6339863) (author), Antoine B. Abchee (19686070) (author), Manal Batrawi (19686073) (author), Athar Khalil (5906330) (author), Ossama K. Abou Hassan (18618628) (author), Steven R. DePalma (9667007) (author), Barbara McDonough (6821369) (author), Mariam T. Arabi (19686076) (author), James S. Ware (7759880) (author), Jonathan G. Seidman (6834896) (author), Christine E. Seidman (6834899) (author)
منشور في: 2020
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513557693988864
author Akl C. Fahed (11514346)
author2 Georges Nemer (295984)
Fadi F. Bitar (19239475)
Samir Arnaout (6339863)
Antoine B. Abchee (19686070)
Manal Batrawi (19686073)
Athar Khalil (5906330)
Ossama K. Abou Hassan (18618628)
Steven R. DePalma (9667007)
Barbara McDonough (6821369)
Mariam T. Arabi (19686076)
James S. Ware (7759880)
Jonathan G. Seidman (6834896)
Christine E. Seidman (6834899)
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Akl C. Fahed (11514346)
Georges Nemer (295984)
Fadi F. Bitar (19239475)
Samir Arnaout (6339863)
Antoine B. Abchee (19686070)
Manal Batrawi (19686073)
Athar Khalil (5906330)
Ossama K. Abou Hassan (18618628)
Steven R. DePalma (9667007)
Barbara McDonough (6821369)
Mariam T. Arabi (19686076)
James S. Ware (7759880)
Jonathan G. Seidman (6834896)
Christine E. Seidman (6834899)
author_role author
dc.creator.none.fl_str_mv Akl C. Fahed (11514346)
Georges Nemer (295984)
Fadi F. Bitar (19239475)
Samir Arnaout (6339863)
Antoine B. Abchee (19686070)
Manal Batrawi (19686073)
Athar Khalil (5906330)
Ossama K. Abou Hassan (18618628)
Steven R. DePalma (9667007)
Barbara McDonough (6821369)
Mariam T. Arabi (19686076)
James S. Ware (7759880)
Jonathan G. Seidman (6834896)
Christine E. Seidman (6834899)
dc.date.none.fl_str_mv 2020-09-04T09:00:00Z
dc.identifier.none.fl_str_mv 10.1161/circgen.120.002991
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Founder_Mutation_in_N_Terminus_of_Cardiac_Troponin_I_Causes_Malignant_Hypertrophic_Cardiomyopathy/27044443
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biological sciences
Genetics
Biomedical and clinical sciences
Cardiovascular medicine and haematology
cardiomyopathy
hypertrophic
death
sudden
cardiac
disease
mutation
risk
dc.title.none.fl_str_mv Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background</h3><p dir="ltr">Cardiac troponin I (<i>TNNI3</i>) gene mutations account for 3% of hypertrophic cardiomyopathy and carriers have a heterogeneous phenotype, with increased risk of sudden cardiac death (SCD). Only one mutation (p.Arg21Cys) has been reported in the N terminus of the protein. In model organisms, it impairs PKA (protein kinase A) phosphorylation, increases calcium sensitivity, and causes diastolic dysfunction. The phenotype of this unique mutation in patients with hypertrophic cardiomyopathy remains unknown.</p><h3>Methods</h3><p dir="ltr">We sequenced 29 families with hypertrophic cardiomyopathy enriched for pediatric-onset disease and identified 5 families with the <i>TNNI3</i> p.Arg21Cys mutation. Using cascade screening, we studied the clinical phenotype of 57 individuals from the 5 families with <i>TNNI3</i> p.Arg21Cys-related cardiomyopathy. We performed survival analysis investigating the age at first SCD in carriers of the mutation.</p><h3>Results</h3><p dir="ltr">All 5 families with <i>TNNI3</i> p.Arg21Cys were from South Lebanon. <i>TNNI3</i> p.Arg21Cys-related cardiomyopathy manifested a malignant phenotype—SCD occurred in 30 (53%) of 57 affected individuals at a median age of 22.5 years. In select carriers without left ventricular hypertrophy on echocardiogram, SCD occurred, myocyte disarray was found on autopsy heart, and tissue Doppler and cardiac magnetic resonance imaging identified subclinical disease features such as diastolic dysfunction and late gadolinium enhancement.</p><h3>Conclusions</h3><p dir="ltr">The TNNI3 p.Arg21Cys mutation has a founder effect in South Lebanon and causes malignant hypertrophic cardiomyopathy with early SCD even in the absence of hypertrophy. Genetic diagnosis with this mutation may be sufficient for risk stratification for SCD.</p><h2>Other Information</h2><p dir="ltr">Published in: Circulation: Genomic and Precision Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/deed.en" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1161/circgen.120.002991" target="_blank">https://dx.doi.org/10.1161/circgen.120.002991</a></p>
eu_rights_str_mv openAccess
id Manara2_20daa44ddaabaf9b83c4e2d018ba2676
identifier_str_mv 10.1161/circgen.120.002991
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/27044443
publishDate 2020
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic CardiomyopathyAkl C. Fahed (11514346)Georges Nemer (295984)Fadi F. Bitar (19239475)Samir Arnaout (6339863)Antoine B. Abchee (19686070)Manal Batrawi (19686073)Athar Khalil (5906330)Ossama K. Abou Hassan (18618628)Steven R. DePalma (9667007)Barbara McDonough (6821369)Mariam T. Arabi (19686076)James S. Ware (7759880)Jonathan G. Seidman (6834896)Christine E. Seidman (6834899)Biological sciencesGeneticsBiomedical and clinical sciencesCardiovascular medicine and haematologycardiomyopathyhypertrophicdeathsuddencardiacdiseasemutationrisk<h3>Background</h3><p dir="ltr">Cardiac troponin I (<i>TNNI3</i>) gene mutations account for 3% of hypertrophic cardiomyopathy and carriers have a heterogeneous phenotype, with increased risk of sudden cardiac death (SCD). Only one mutation (p.Arg21Cys) has been reported in the N terminus of the protein. In model organisms, it impairs PKA (protein kinase A) phosphorylation, increases calcium sensitivity, and causes diastolic dysfunction. The phenotype of this unique mutation in patients with hypertrophic cardiomyopathy remains unknown.</p><h3>Methods</h3><p dir="ltr">We sequenced 29 families with hypertrophic cardiomyopathy enriched for pediatric-onset disease and identified 5 families with the <i>TNNI3</i> p.Arg21Cys mutation. Using cascade screening, we studied the clinical phenotype of 57 individuals from the 5 families with <i>TNNI3</i> p.Arg21Cys-related cardiomyopathy. We performed survival analysis investigating the age at first SCD in carriers of the mutation.</p><h3>Results</h3><p dir="ltr">All 5 families with <i>TNNI3</i> p.Arg21Cys were from South Lebanon. <i>TNNI3</i> p.Arg21Cys-related cardiomyopathy manifested a malignant phenotype—SCD occurred in 30 (53%) of 57 affected individuals at a median age of 22.5 years. In select carriers without left ventricular hypertrophy on echocardiogram, SCD occurred, myocyte disarray was found on autopsy heart, and tissue Doppler and cardiac magnetic resonance imaging identified subclinical disease features such as diastolic dysfunction and late gadolinium enhancement.</p><h3>Conclusions</h3><p dir="ltr">The TNNI3 p.Arg21Cys mutation has a founder effect in South Lebanon and causes malignant hypertrophic cardiomyopathy with early SCD even in the absence of hypertrophy. Genetic diagnosis with this mutation may be sufficient for risk stratification for SCD.</p><h2>Other Information</h2><p dir="ltr">Published in: Circulation: Genomic and Precision Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/deed.en" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1161/circgen.120.002991" target="_blank">https://dx.doi.org/10.1161/circgen.120.002991</a></p>2020-09-04T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1161/circgen.120.002991https://figshare.com/articles/journal_contribution/Founder_Mutation_in_N_Terminus_of_Cardiac_Troponin_I_Causes_Malignant_Hypertrophic_Cardiomyopathy/27044443CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/270444432020-09-04T09:00:00Z
spellingShingle Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
Akl C. Fahed (11514346)
Biological sciences
Genetics
Biomedical and clinical sciences
Cardiovascular medicine and haematology
cardiomyopathy
hypertrophic
death
sudden
cardiac
disease
mutation
risk
status_str publishedVersion
title Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
title_full Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
title_fullStr Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
title_full_unstemmed Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
title_short Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
title_sort Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy
topic Biological sciences
Genetics
Biomedical and clinical sciences
Cardiovascular medicine and haematology
cardiomyopathy
hypertrophic
death
sudden
cardiac
disease
mutation
risk